List of Excipients in Branded Drug FLUVOXAMINE MALEATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aidarex Pharmaceuticals LLC	FLUVOXAMINE MALEATE	fluvoxamine maleate	33261-683	CARNAUBA WAX
Aidarex Pharmaceuticals LLC	FLUVOXAMINE MALEATE	fluvoxamine maleate	33261-683	FERRIC OXIDE YELLOW
Aidarex Pharmaceuticals LLC	FLUVOXAMINE MALEATE	fluvoxamine maleate	33261-683	HYPROMELLOSE 2910

Generic Drugs Containing FLUVOXAMINE MALEATE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	fluvoxamine maleate	0228-2848	AMMONIO METHACRYLATE COPOLYMER
Actavis Pharma Inc	fluvoxamine maleate	0228-2848	AMMONIO METHACRYLATE COPOLYMER TYPE B
Actavis Pharma Inc	fluvoxamine maleate	0228-2848	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in FLUVOXAMINE MALEATE?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
2	AMMONIO METHACRYLATE COPOLYMER

Fluvoxamine Maleate Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Fluvoxamine maleate is an established generic selective serotonin reuptake inhibitor with limited active-ingredient exclusivity and a broad opportunity set in formulation, supply-chain, and differentiated dosage-form technologies. Immediate-release fluvoxamine tablets are commercially mature and price competitive. The strongest opportunities are in low-cost, robust excipient systems, modified-release products, pediatric and geriatric administration, multiparticulates, and abuse-resistant or adherence-oriented delivery formats.

What is the FDA status of fluvoxamine maleate?

Fluvoxamine maleate is FDA-approved for obsessive-compulsive disorder. Immediate-release tablets are available in 25 mg, 50 mg, and 100 mg strengths. An extended-release capsule product, Luvox CR, was approved for OCD in adults and adolescents aged 18 years and older under NDA 21-519. [1,2]

Product	Dosage form	Strengths	Primary indication	Regulatory pathway
Luvox	Immediate-release tablet	25, 50, 100 mg	OCD	NDA
Generic fluvoxamine maleate	Immediate-release tablet	25, 50, 100 mg	OCD	ANDA
Luvox CR	Extended-release capsule	100, 150 mg	OCD in adults	NDA
Compounded or specialty formulations	Varies	Varies	Usually off-label or individualized	Pharmacy compounding or 505(b)(2) potential

FDA-approved fluvoxamine products are prescription medicines. The active ingredient is the maleate salt of fluvoxamine, and the product is administered orally. FDA labeling identifies clinically important CYP-mediated drug-interaction risks, including potent inhibition of CYP1A2 and CYP2C19. [1,2]

When did fluvoxamine maleate lose patent exclusivity?

The original immediate-release fluvoxamine product is off patent, and generic fluvoxamine maleate tablets have been marketed for many years. The immediate-release market is therefore governed primarily by ANDA competition, manufacturing cost, supply reliability, and distributor access rather than compound-patent exclusivity.

Luvox CR had separate formulation-related intellectual-property considerations because its release profile depends on multiparticulate or coated-particle technology rather than a conventional immediate-release tablet. Historical Orange Book records should be reviewed by product and patent listing because the relevant commercial question is whether a listed patent remains active for the specific NDA product and strength. [3]

Exclusivity timeline

Milestone	Approximate period or status
Original Luvox approval	1994
Generic immediate-release fluvoxamine entry	Mature generic market
Luvox CR approval	2008
Current immediate-release commercial position	Off-patent, multi-source
Current opportunity	Formulation differentiation and operational execution

The principal commercial barrier for a new immediate-release fluvoxamine product is not the expired active-ingredient patent. It is the ability to obtain FDA approval, meet bioequivalence requirements, secure reliable API and excipient supply, and compete against established ANDA holders.

What patents protect fluvoxamine maleate products?

Immediate-release tablets

Immediate-release fluvoxamine maleate tablets are generally protected by expired composition-of-matter and product patents, if any, rather than by currently valuable active-ingredient exclusivity. A new entrant would normally pursue an ANDA referencing the approved immediate-release product and would evaluate Orange Book patent listings, regulatory exclusivity, and any applicable labeling restrictions. [3,4]

Excipient selection alone normally does not create meaningful patent protection. Conventional use of lactose, microcrystalline cellulose, starch, croscarmellose sodium, colloidal silicon dioxide, or magnesium stearate is unlikely to support a durable blocking position unless the formulation has a specific, non-obvious functional relationship with dissolution, stability, manufacturability, or pharmacokinetics.

Extended-release formulations

Extended-release fluvoxamine products have greater potential for formulation patents. Protectable subject matter may include:

• Coated drug-containing pellets or beads
• Polymer membrane systems
• pH-dependent release layers
• Ethylcellulose or acrylic polymer coatings
• Hypromellose matrices
• Multiparticulate capsules
• Specific dissolution profiles
• Reduced food effect
• Reduced peak-to-trough fluctuation
• Manufacturing methods that produce a reproducible release profile

The commercial value of this protection depends on whether the patent claims cover the product as sold, whether the claims survive validity challenges, and whether an ANDA applicant can design around the formulation.

How many patents cover fluvoxamine maleate?

The relevant patent count depends on the product category.

Product category	Patent exposure
Immediate-release fluvoxamine tablet	Low current patent exposure; mature generic market
Extended-release fluvoxamine capsule	Higher formulation-related exposure
Pediatric liquid	Potentially new formulation and method-of-use claims
Orally disintegrating tablet	Potential formulation and process claims
Fixed-dose combination	Potential combination and method-of-use claims
Novel delivery system	New formulation, device, or manufacturing claims

Patent counts should not be treated as a proxy for commercial strength. One enforceable formulation patent can matter more than numerous narrow process patents. For fluvoxamine, the strongest potential claims are likely to concern release control, particle coating, stability, taste masking, and product-specific bioequivalence performance.

What excipients are used in fluvoxamine maleate tablets and capsules?

The excipient profile differs materially between immediate-release and extended-release products.

Immediate-release tablet excipients

Commercial fluvoxamine maleate tablets commonly use combinations of:

• Lactose monohydrate
• Microcrystalline cellulose
• Pregelatinized starch or other starch excipients
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate or sodium stearyl fumarate
• Film-coating polymers
• Titanium dioxide and permitted colorants

Exact compositions vary by manufacturer and strength. DailyMed product labels should be used for product-specific excipient confirmation because generic suppliers may change inactive ingredients across manufacturers and dosage strengths. [5]

The immediate-release design objective is usually rapid and reproducible disintegration, adequate tablet hardness, low friability, and stable assay through shelf life. The maleate salt can be incorporated into conventional direct-compression or wet-granulation platforms, subject to particle-size distribution, flow, lubrication, and moisture-control requirements.

Extended-release capsule excipients

Luvox CR uses a multiparticulate extended-release design. Labeling identifies inactive ingredients associated with pellet manufacture and coating, including sugar spheres, hypromellose, ethylcellulose, dibutyl sebacate, talc, gelatin, titanium dioxide, and capsule colorants. [2]

This architecture creates a more valuable excipient strategy because the excipients perform a release-controlling function. The commercial product is not defined only by the API and capsule shell. It is defined by pellet size, drug loading, coating weight gain, polymer permeability, plasticization, and final dissolution behavior.

Which excipient strategies offer the best commercial opportunities?

1. Low-cost immediate-release tablets

The lowest-risk opportunity is a conventional generic tablet designed around low manufacturing cost and reliable scale-up.

Preferred characteristics include:

• Direct compression where powder flow permits
• Minimal excipient count
• Robust content uniformity
• Low sensitivity to lubricant overmixing
• Low moisture uptake
• Stable film coating
• Common, dual-source excipients
• Compatibility with high-speed tablet presses

Microcrystalline cellulose can improve compactibility, while croscarmellose sodium can support rapid disintegration. Colloidal silicon dioxide can improve flow, but excessive use can impair compaction or create blend segregation. Magnesium stearate is economical but requires controlled lubrication time because over-lubrication can delay dissolution.

The commercial advantage is cost and supply resilience, not clinical differentiation.

2. Lactose-free or low-lactose tablets

Lactose is widely used in oral solid dosage forms, but lactose-free products can address patients with excipient sensitivity, dietary preferences, or pharmacy substitution requirements. A lactose-free formulation can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or coprocessed excipients.

A lactose-free claim must be supported by the complete formulation and labeling. The opportunity is commercially modest but can help a supplier differentiate within a crowded multi-source market.

3. Orally disintegrating tablets

An orally disintegrating fluvoxamine product could target patients with dysphagia, psychiatric adherence challenges, or difficulty swallowing tablets. Mannitol is attractive for mouthfeel and cooling sensation. Crospovidone, croscarmellose sodium, and low-substituted hydroxypropyl cellulose can accelerate disintegration.

The major technical problem is taste. Fluvoxamine maleate can require taste masking through:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Lipid-based barriers
• pH-modifying microenvironments
• Sweetener and flavor systems

An ODT would likely require a new formulation program rather than a simple ANDA approach if no suitable reference product exists. Depending on the proposed labeling and clinical bridge, a 505(b)(2) pathway may be relevant. [4]

4. Oral liquid and pediatric formulations

A ready-to-use oral liquid could expand administration options for patients unable to swallow tablets. Key formulation variables include:

• Salt solubility and pH
• Chemical stability in aqueous media
• Preservative compatibility
• Container-closure adsorption
• Flavor and taste masking
• Dose-measurement accuracy
• Microbial control
• Sedimentation or precipitation

Potential excipients include purified water, buffering agents, sweeteners, viscosity modifiers, preservatives, flavorants, and solubilizers. A liquid product must account for fluvoxamine’s interaction profile and avoid excipients that create avoidable tolerability or dosing concerns.

Commercial opportunities are strongest in hospital, specialty-pharmacy, pediatric, and long-term-care channels. Pediatric use would require careful regulatory positioning because the approved Luvox CR labeling is directed to adults, while product-specific pediatric claims require supporting evidence and FDA review. [1,2]

5. Extended-release multiparticulates

Multiparticulates provide the most technically defensible excipient opportunity. A generic or follow-on extended-release product could use:

• Sugar spheres or inert starter cores
• Hypromellose drug-layer binders
• Ethylcellulose membranes
• Methacrylate copolymers
• Polyethylene glycol or other pore-forming agents
• Dibutyl sebacate or triethyl citrate plasticizers
• Talc as an anti-tacking agent
• Hypromellose capsule shells

Critical development variables include coating uniformity, pellet size distribution, drug loading, curing conditions, residual solvent control, and dissolution across pH conditions.

A successful product must match the reference release profile closely enough to satisfy FDA bioequivalence requirements. Food-effect behavior is also important. A formulation that produces excessive alcohol-induced dose dumping, high variability, or a clinically different peak concentration can face regulatory and commercial problems.

6. Sprinkle capsules

A sprinkle formulation containing coated pellets could address patients who cannot swallow capsules. The product must maintain release performance after opening and sprinkling on an approved soft food or liquid. Critical requirements include:

• Pellet integrity
• No crushing or chewing
• Stable release after capsule opening
• Acceptable taste
• Low segregation during administration
• Clear patient instructions

This format can support a differentiated 505(b)(2) product or a product-specific formulation strategy, depending on the reference and proposed claims.

How strong is the patent estate for fluvoxamine excipient formulations?

The patent estate is strongest where excipients create a measurable pharmaceutical function.

Excipient strategy	Patent strength potential	Commercial value
Standard lactose-MCC tablet	Low	Manufacturing-cost advantage
Lactose-free tablet	Low to moderate	Niche differentiation
ODT with taste masking	Moderate	Patient-convenience opportunity
Oral liquid	Moderate	Pediatric and institutional channels
Coated multiparticulate capsule	Moderate to high	Modified-release differentiation
Sprinkle capsule	Moderate	Adherence and swallowing benefit
Novel polymer release system	High if clinically differentiated	Potential 505(b)(2) platform

A patent claim directed only to a list of excipients is vulnerable if the combination is predictable. Stronger claims define measurable parameters such as dissolution windows, coating thickness, particle-size distributions, drug-release kinetics, stability limits, or reduced pharmacokinetic variability.

What manufacturing and intellectual-property barriers exist?

The key manufacturing barriers are process control and analytical reproducibility.

Immediate-release manufacturing barriers

Immediate-release tablets are relatively accessible, but manufacturers must control:

• API particle size
• Blend uniformity
• Segregation
• Compression force
• Tablet hardness
• Disintegration time
• Lubrication
• Film-coat uniformity

Fluvoxamine products also require careful control of assay and degradation products. A low-cost formulation that fails dissolution or stability testing has no commercial value.

Extended-release manufacturing barriers

Extended-release products create more substantial barriers:

• Uniform drug layering on pellets
• Consistent polymer coating
• Control of coating weight gain
• Reproducible curing
• Low pellet-to-pellet variability
• Capsule fill-weight control
• Release testing across multiple pH conditions
• Scale-up from laboratory fluid-bed equipment

These processes can support trade-secret protection even when patent claims are narrow. Manufacturing know-how may become more important than the excipient list itself.

What FDA and Orange Book issues affect generic entry?

An ANDA applicant for immediate-release fluvoxamine maleate must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Relevant issues include strength, dosage form, route of administration, inactive ingredients, labeling, and dissolution performance. [3,4]

Paragraph IV challenges

Paragraph IV litigation is more relevant to any remaining listed patent associated with an extended-release or other differentiated product than to mature immediate-release tablets. An ANDA applicant making a Paragraph IV certification must address the patent’s validity, enforceability, or infringement risk. FDA approval timing can be affected by litigation and statutory stays. [4]

30-month stay and first-filer economics

Where an Orange Book-listed patent remains relevant, a timely Paragraph IV notice can trigger litigation and potentially a 30-month stay. A first substantially complete ANDA applicant may qualify for 180-day generic exclusivity if statutory conditions are met. [4]

For a mature immediate-release product, the commercial value of first-filer status is usually lower than it was during initial genericization because multiple suppliers and substitution pressure can rapidly erode pricing.

Which companies are challenging or competing with fluvoxamine products?

The immediate-release competitive field consists of established generic manufacturers and distributors rather than a single dominant innovator. Competition is typically based on:

• Wholesale acquisition cost
• Medicaid and commercial-plan contracting
• Supply continuity
• Manufacturing location
• Shortage performance
• Distributor relationships
• Available strengths
• Tablet appearance and packaging
• Formulary and substitution access

The broader therapeutic market includes fluoxetine, sertraline, paroxetine, escitalopram, and clomipramine. These products compete for OCD treatment and related psychiatric prescribing, although they differ in tolerability, interaction profile, approved indications, and dosage forms.

How does fluvoxamine compare with competing SSRIs from an excipient perspective?

Drug	Common dosage forms	Excipient opportunity	Competitive position
Fluvoxamine maleate	IR tablets; ER capsules	ODT, liquid, multiparticulate ER	Narrower approved indication base
Sertraline hydrochloride	Tablets, oral concentrate	Taste masking, liquid stability	Large generic market
Fluoxetine hydrochloride	Capsules, tablets, solution	Liquid and capsule platforms	Broad indication base
Paroxetine hydrochloride	Tablets, suspension, CR tablets	Modified release and liquid	Larger formulation history
Escitalopram oxalate	Tablets, solution	ODT and liquid	Strong adherence and substitution competition
Clomipramine hydrochloride	Capsules	Capsule and tolerability-oriented formats	Older tricyclic platform

Fluvoxamine’s principal disadvantage is market scale. Its principal opportunity is specialization: OCD-focused products, swallowing-friendly dosage forms, controlled release, and supply reliability.

What licensing deals could support commercial entry?

Licensing opportunities are most credible in four areas:

1. Drug-device or delivery platforms: ODT, oral-film, sprinkle, or liquid technologies that already have manufacturing and regulatory history.
2. Polymer coating systems: Proprietary controlled-release coatings with established scale-up data.
3. Specialty manufacturing: Contract development and manufacturing organizations with fluid-bed coating capability.
4. Regional rights: Local commercialization in markets where fluvoxamine remains under-supplied or where modified-release products have limited competition.

A license is commercially attractive when it transfers validated process knowledge, bioequivalence data, or regulatory documentation. A simple license to use commonly available excipients has limited strategic value.

What generic launch scenarios exist for fluvoxamine maleate?

Scenario 1: Low-cost immediate-release tablet

This is the most accessible route. The product competes on cost, availability, and distribution. Margin pressure is high, and supply interruptions can create temporary pricing opportunities.

Scenario 2: Differentiated ODT

This route targets adherence and swallowing limitations. It requires taste masking, mechanical robustness, and a clear regulatory strategy. Patent value is higher than for a conventional tablet but depends on whether the taste-masking and disintegration system is genuinely non-obvious.

Scenario 3: Oral liquid

A liquid can reach pediatric, geriatric, institutional, and specialty-pharmacy segments. Stability, preservative performance, and taste are the principal development risks.

Scenario 4: Extended-release or sprinkle product

This has the highest formulation complexity and potentially the strongest pricing opportunity. It also carries the greatest bioequivalence, manufacturing, and intellectual-property risk.

What is the revenue exposure and commercial upside?

Immediate-release fluvoxamine is a mature, relatively small generic opportunity compared with high-volume SSRIs such as sertraline, fluoxetine, and escitalopram. Revenue depends heavily on channel access and the number of active suppliers.

The most attractive revenue pools are likely to come from:

• Hospital and institutional supply contracts
• Products with reliable shortage performance
• Specialty pharmacy distribution
• Pediatric or dysphagia-focused formulations
• Extended-release products with limited competition
• Regional markets with few registered suppliers

A conventional tablet may offer predictable but low-margin revenue. A differentiated formulation can support higher gross margin, but development costs and regulatory requirements rise sharply.

Key Takeaways

• Immediate-release fluvoxamine maleate tablets are a mature generic market with limited active-ingredient patent leverage.
• Excipient selection is commercially important for cost, stability, manufacturability, and bioequivalence, but conventional excipient combinations provide weak patent protection.
• The strongest formulation opportunities are extended-release multiparticulates, orally disintegrating tablets, oral liquids, and sprinkle capsules.
• Extended-release products offer the best potential for formulation patents and pricing differentiation.
• Taste masking, polymer coating, dissolution control, and manufacturing reproducibility are the main technical barriers.
• Generic entry risk is high for conventional immediate-release tablets and lower, but more technically complex, for differentiated modified-release products.
• A licensing strategy should focus on validated delivery technology, coating know-how, regulatory data, and specialized manufacturing capacity.
• The commercial case is stronger for focused specialty products than for another undifferentiated immediate-release tablet.

FAQs

Is fluvoxamine maleate still patent protected?

The original immediate-release fluvoxamine product is off patent and is marketed generically. Extended-release formulations may have separate historical formulation patents and should be evaluated through current Orange Book records.

Can fluvoxamine maleate be formulated as an oral liquid?

Yes. An oral liquid would require development of a stable, palatable formulation with suitable preservative, container-closure, dosing, and microbiological controls.

Which excipient is best for a fluvoxamine extended-release formulation?

No single excipient determines performance. Ethylcellulose, methacrylate polymers, hypromellose, plasticizers, pore-forming agents, and inert cores can be combined in multiparticulate systems, with coating process control determining the final release profile.

Is an orally disintegrating fluvoxamine product commercially attractive?

It can be attractive for patients with swallowing or adherence challenges, but taste masking and regulatory bridging are central development requirements.

Does fluvoxamine have biosimilar risk?

No. Fluvoxamine maleate is a small-molecule drug, so the relevant competitive risks are generic substitution, formulation competition, and 505(b)(2) products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Luvox (fluvoxamine maleate) tablets prescribing information.
2. U.S. Food and Drug Administration. (2023). Luvox CR (fluvoxamine maleate) extended-release capsules prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry.
5. National Library of Medicine. (2024). DailyMed: Fluvoxamine maleate product labeling and inactive ingredient information.